title: [Clinical Comparation of Two Kinds of Chemotherapy Regimen in the Treatment of Elderly MDS Patients with AML Transformed by Abnormal Proliferation of Bone Marrow].
abstract: OBJECTIVE
  To investigate the clinical efficacy and safety of "3+7" regimen and decitabine + HAG pre-excitation regimen in the treatment of elderly MDS patients with AML transformed by abnormal proliferation of bone marrow.
  
  
  METHODS
  Fifty elderly patients with AML transformed by abnormal proliferation of bone marrow in the period from March 2012 to May 2014 were chosen and randomly divided into 2 groups including A group (25 elderly patients treated with "3+7" regimen) and B group (25 elderly patients treated with decitabine+HAG pre-excitation regimen), and the clinical effeicacy, the median survival time and the incidence of drug adverse effects in 2 groups were compared.
  
  
  RESULTS
  The clinical total remission rate in B group was significantly higher than that in A group(P<0.05). The leukopenia time, neutropenia time and recovery time of leukocyte and neutrophilia in B group were significantly shorter than those in A group, the differences were statistically significant (P<0.05). The rate of lung infection in B group was significantly lower than that in A group. There was no significant difference in the incidence of other drug adverse effects between 2 groups(P>0.05). The life quality of patients in B group was significantly prior to patients in A group, and the difference was statistically significant (P<0.05). The average survival time and the median survival time of patients in B group was significantly longer than those in A group(P<0.05).
  
  
  CONCLUSIONS
  Compared with "3+7" regimen, the decitabine+HAG pre-excitation regimen in the treatment of elderly patients with AML transformed by abnormal proliferation of bone marrow can efficiently delay the disease progression process, shorten the time of bone marrow suppression, decrease the rate of lung infection and prolong the survival time.
authors: Department of Hematology, Wuxi Municipal Second People's Hospital Affiliated to Nanjing Medical University, Wuxi 214002,Jiangsu Province, China.
authors: Zhong-Hao
authors: ZH
authors: Zhou
authors: Department of Hematology, Wuxi Municipal Second People's Hospital Affiliated to Nanjing Medical University, Wuxi 214002,Jiangsu Province, China.
authors: Xiao-Hong
authors: XH
authors: Zhao
authors: Department of Hematology, Wuxi Municipal Second People's Hospital Affiliated to Nanjing Medical University, Wuxi 214002,Jiangsu Province, China.
authors: Shi-Yun
authors: SY
authors: Lu
authors: Department of Hematology, Wuxi Municipal Second People's Hospital Affiliated to Nanjing Medical University, Wuxi 214002,Jiangsu Province, China.
authors: Chen
authors: C
authors: Wang
authors: Department of Hematology, Wuxi Municipal Second People's Hospital Affiliated to Nanjing Medical University, Wuxi 214002,Jiangsu Province, China. E-mail: zzh0810@163.com.
authors: Zhi
authors: Z
authors: Wang
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols; D001374:Azacitidine / Q000031:analogs & derivatives; D001853:Bone Marrow; D049109:Cell Proliferation; D000077209:Decitabine; D006801:Humans; D015470:Leukemia, Myeloid, Acute; D009190:Myelodysplastic Syndromes; D009503:Neutropenia; D011788:Quality of Life; D016896:Treatment Outcome
chemical_list: D000077209:Decitabine; D001374:Azacitidine